Cara Therapeutics Inc (CARA)
0.7565
0.00 (0.00%)
USD |
NASDAQ |
May 01, 16:00
0.7565
0.00 (0.00%)
After-Hours: 20:00
Cara Therapeutics Cash from Financing (Quarterly): 36.48M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 36.48M |
| September 30, 2023 | 1.116M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.56M |
| December 31, 2022 | 0.022M |
| September 30, 2022 | 0.104M |
| June 30, 2022 | 0.182M |
| March 31, 2022 | 0.003M |
| December 31, 2021 | 45.29M |
| September 30, 2021 | 0.339M |
| June 30, 2021 | 0.293M |
| March 31, 2021 | 0.688M |
| December 31, 2020 | 38.47M |
| September 30, 2020 | 0.395M |
| June 30, 2020 | 0.201M |
| March 31, 2020 | 0.075M |
| December 31, 2019 | 0.028M |
| September 30, 2019 | 138.37M |
| June 30, 2019 | 3.974M |
| March 31, 2019 | 0.234M |
| December 31, 2018 | 0.544M |
| September 30, 2018 | 93.96M |
| Date | Value |
|---|---|
| June 30, 2018 | 16.04M |
| March 31, 2018 | 0.263M |
| December 31, 2017 | 0.183M |
| September 30, 2017 | 0.151M |
| June 30, 2017 | 87.44M |
| March 31, 2017 | 0.149M |
| December 31, 2016 | 0.083M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.04M |
| December 31, 2015 | -0.183M |
| September 30, 2015 | 75.74M |
| June 30, 2015 | 0.029M |
| March 31, 2015 | 0.006M |
| December 31, 2014 | 0.109M |
| September 30, 2014 | 0.09M |
| June 30, 2014 | 0.019M |
| March 31, 2014 | 57.77M |
| December 31, 2013 | -0.311M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 7.335M |
| March 31, 2013 | 1.392M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Jun 2023
138.37M
Maximum
Sep 2019
14.03M
Average
0.339M
Median
Sep 2021
Cash from Financing (Quarterly) Benchmarks
| Nektar Therapeutics | 0.012M |
| Stereotaxis Inc | 0.026M |
| Cerus Corp | 1.183M |
| Avid Bioservices Inc | 0.085M |
| Rigel Pharmaceuticals Inc | 0.486M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -17.37M |
| Cash from Investing (Quarterly) | -30.20M |
| Free Cash Flow | -94.45M |
| Free Cash Flow Per Share (Quarterly) | -0.3565 |
| Free Cash Flow to Equity (Quarterly) | -19.42M |
| Free Cash Flow Yield | -230.6% |